Physician profile
David Januszewski
NPI 1659892776
$9,027.68
in general payments reported to CMS, 2019-2025
36 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what 76% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,465 · 2020: $2,123 · 2021: $343 · 2022: $1,182 · 2023: $566 · 2024: $1,931 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451 · Travel and Lodging: $881 · Long Term Medical Supply Or Device Loan: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,450.72 |
| Travel and Lodging | $881.01 |
| Long Term Medical Supply Or Device Loan | $584.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medinc of Texas | $1,270.58 | 2020-2024 | |
| Integra Lifesciences Corporation | $1,069.10 | 2019-2025 | Integra Dermal Regeneration Template, Acell, Integra |
| Treace Medical Concepts, INC. | $945.00 | 2022-2025 | |
| Stryker Corporation | $806.85 | 2019-2025 | N/A, Spy-Phi System, Na |
| Mission Medical Distribution, LLC | $789.38 | 2024-2025 | |
| Medical Device Business Services, INC. | $601.99 | 2019-2020 | |
| Wright Medical Technology, INC. | $544.76 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $355.68 | 2021-2025 | Nuzyra |
| Arthrex, INC. | $292.65 | 2024 | |
| Organogenesis INC. | $253.37 | 2022-2025 | Puraply, Nushield |
| Sanara Medtech INC. | $223.00 | 2023-2024 | Celleraterx |
| Abbvie INC. | $190.84 | 2023-2025 | |
| Melinta Therapeutics, LLC | $181.25 | 2020-2022 | |
| Smith+Nephew, INC. | $171.95 | 2022-2023 | Stravix, Grafix Pl |
| Trilliant Surgical LLC. | $168.48 | 2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $152.29 | 2025 | |
| Bone Support INC. | $128.34 | 2025 | Ceramentbone Void Filler, Cerament G |
| Depuy Synthes Sales INC. | $115.88 | 2022-2025 | Motoband, Va-Lcp |
| Anika Therapeutics, INC. | $110.08 | 2021 | |
| Convatec INC. | $91.79 | 2024-2025 | |
| Kerecis Limited | $88.09 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Kci USA, INC. | $49.50 | 2021-2023 | V.A.C. Dermatac, V.A.C. Veraflo Cleanse Choice |
| Flower Orthopedics Coporation | $45.66 | 2022 | |
| Osteoremedies, LLC | $44.67 | 2025 | Osteoboost Select 5cc |
| Ibsa Pharma INC. | $41.63 | 2023-2024 | Tirosint, Licart, Licart |
| Medtronic, INC. | $38.35 | 2022-2025 | Inceptiv |
| Bioventus LLC | $38.32 | 2022-2023 | Exogen Ultrasound Bone Healing System |
| Acera Surgical, INC. | $34.19 | 2021-2023 | Restrata Wound Matrix |
| Musculoskeletal Transplant Foundation INC. | $33.68 | 2021 | |
| Atland Pharmaceuticals, LLC | $30.39 | 2024 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Nabriva Therapeutics, Plc | $25.98 | 2021 | |
| Hartmann USA, INC. | $23.26 | 2023 | Zetuvit Plus |
| Cardiovascular Systems INC. | $21.14 | 2022 | |
| Nevro Corp. | $18.50 | 2022 | |
| Grt US Holding, INC. | $17.12 | 2022 | |
| Stimlabs LLC | $13.94 | 2025 | Geistlich Derma-Gide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Januszewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.